Lucentis every 4 weeks — Competitive Intelligence Brief

Lucentis every 4 weeks (Lucentis every 4 weeks) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: VEGF-A inhibitor (monoclonal antibody fragment). Area: Ophthalmology.

marketed VEGF-A inhibitor (monoclonal antibody fragment) VEGF-A Ophthalmology Small molecule

Target snapshot

Lucentis every 4 weeks (Lucentis every 4 weeks) — Retinal Consultants of Arizona. Lucentis (ranibizumab) blocks vascular endothelial growth factor A (VEGF-A) to inhibit abnormal blood vessel growth and reduce fluid leakage in the retina.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lucentis every 4 weeks TARGET	Lucentis every 4 weeks	Retinal Consultants of Arizona	marketed	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A
Aflibercept (Eylea)	Aflibercept (Eylea)	Ahmad Zeeshan Jamil	marketed	VEGF inhibitor / Soluble decoy receptor	VEGF-A, VEGF-B, PlGF (Placental Growth Factor)
Aflibercept and ranibizumab	Aflibercept and ranibizumab	Instituto de Olhos de Goiania	marketed	Anti-VEGF agent	VEGF-A (and VEGF-B for aflibercept)
Lucentis (ranibizumab)	Lucentis (ranibizumab)	Samsung Bioepis Co., Ltd.	marketed	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A (Vascular Endothelial Growth Factor A)
Rescue Intravitreal Aflibercept Injection	Rescue Intravitreal Aflibercept Injection	Southeast Retina Center, Georgia	marketed	VEGF inhibitor / Recombinant fusion protein	VEGF-A, VEGF-B, PlGF (placental growth factor)
aflibercept + FOLFIRI	aflibercept + FOLFIRI	CR-CSSS Champlain-Charles-Le Moyne	marketed	VEGF inhibitor (fusion protein) + chemotherapy combination	VEGF-A, VEGF-B, PlGF (aflibercept component); topoisomerase I and thymidylate synthase (FOLFIRI component)
Ranibizumab and Aflibercept	Ranibizumab and Aflibercept	Instituto de Olhos de Goiania	marketed	Anti-VEGF agent	VEGF-A (vascular endothelial growth factor-A)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (VEGF-A inhibitor (monoclonal antibody fragment) class)

1. Retinal Consultants of Arizona · 2 drugs in this class
2. Ain Shams University · 1 drug in this class
3. Greater Houston Retina Research · 1 drug in this class
4. Hoffmann-La Roche · 1 drug in this class
5. LEANDRO CABRAL ZACHARIAS · 1 drug in this class
6. Medical University of Vienna · 1 drug in this class
7. AbbVie · 1 drug in this class
8. Samsung Bioepis Co., Ltd. · 1 drug in this class